Amgen’s D-mab wins blockbuster approval in Europe

Amgen (NASDAQ: AMGN) can soon start watching the cash roll in for denosumab. After testing the bone-loss drug in a battery of late-stage trials, the therapy--to be sold as Prolia--won its first regulatory approval in Europe. GlaxoSmithKline (NYSE: GSK) will now collaborate with Amgen on the commercialization work on the continent for a drug that is expected to earn billions of dollars a year and help position the big biotech for the decade ahead. Regulators approved the drug as a treatment...